Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CytoMed Therapeutics Limited (GDTC)
Singapore, CE, SG
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.89% | +5.40% | -20.28% | -24.57% | -59.93% | -42.58% | -66.11% | -75.02% | -80.77% | -80.77% | -80.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+377.4% ★ Q4'25: +20.3% (vs Q3'24)
-
EPS growth Biotechnology: +29.7%-62.5% Q4'25: -128.2% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,618.0% Q4'25: -1,397.7% (vs Q3'24)
-
EBIT margin Biotechnology: +0.0%-1,416.0% Q4'25: -1,403.1% (vs Q3'24)
-
ROIC Biotechnology: -16.1%-67.1% Q4'25: -139.9% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%+0.9% ★ Q4'25: +2.2% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.14× Q4'25: -0.07× (vs Q3'24)
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
290.6K
est: 520.0K (-44.1%)
|
52.0K
est: 571.0K (-90.9%)
|
248.3K
est: 520.0K (-52.3%)
|
| EBITDA |
-2.94M
est: -312.0K (-841.6%)
|
-1.79M
est: -342.6K (-422.6%)
|
-3.34M
est: -312.0K (-971.1%)
|
| EBIT |
-3.02M
est: -312.0K (-866.4%)
|
-1.88M
est: -342.6K (-449.4%)
|
-3.52M
est: -312.0K (-1,026.7%)
|
| Net Income |
-3.13M
est: -3.00M (-4.4%)
|
-1.88M
est: -1.75M (-7.8%)
|
-3.05M
est: -1.98M (-53.9%)
|
| SGA |
370.7K
est: 3.58M (-89.6%)
|
1.27M
est: 4.15M (-69.5%)
|
1.12M
est: 3.78M (-70.3%)
|
| EPS |
-0.29
est: -0.26 (-11.5%)
|
-0.16
est: -0.15 (-6.7%)
|
-0.26
est: -0.17 (-52.9%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Finance Limited | 4.65M | 42.54% | 4.65M | — | 4.65M | — | CO | Virgin Islands | 2023-04-21 | ↗ |
| 2 | Chee Kong | 3.16M | 28.86% | 3.16M | — | 3.16M | — | IN | of Singapore | 2023-04-21 | ↗ |
| 3 | Limited | 1.34M | 11.59% | 1.34M | — | 1.34M | — | CO | Republic of Singapore | 2024-02-14 | ↗ |
| 4 | Wang Shu | 883.9K | 7.66% | 883.9K | — | 883.9K | — | IN | Sweden | 2024-02-14 | ↗ |
| 5 | Zeng Jieming | 589.2K | 5.11% | 589.2K | — | 589.2K | — | IN | People’s Republic of China | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jieming Zeng | Chief Scientific & Medical Officer and Director | 102.0K | — |
| Chee Kong Choo | Executive Chairman | 38.1K | male |
| Tien Wee Luk | Chief Clinical Officer | — | — |
| Yoong Ying Tan | Chief Corporation Officer | — | female |
| Yvonne Goh | Chief Financial Officer | — | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GDTC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
